![]() |
| Courtesy of Wake Forest University School of Medicine |
It’s happening right now in North Carolina:
Regenerative medicine became prominent here as early as 1998, when some 80 scientists (about 25 of them students) gathered at the North Carolina Biotechnology Center. They exchanged ideas and shared their research findings on engineering blood vessels, bone, fat, skin and other tissues and organs.
Every year since, the gathering now known as the North Carolina Tissue Engineering and Regenerative Medicine (NCTERM) Conference has grown in attendance and scope.
The most high-profile practitioners of this “body-building” approach to therapies are Anthony Atala, M.D., director of the Wake Forest Institute for Regenerative Medicine, and Duke cord-blood pioneer Joanne Kurtzberg, M.D.
Atala’s successes in the lab are being translated into commercial potential by Tengion, a publicly traded Pennsylvania company that maintains its research team close to Atala’s, in Winston-Salem.
Kurtzberg, meanwhile, runs the Carolinas Cord Blood Bank, one of the largest public cord blood banks in the world, and oversees the state-of-the-art Translational Cell Therapy Center, both on the Duke campus.
The Pentagon has put more than $42 million into a multi-campus consortium involving Atala and others, seeking to develop battle-wound treatments:
The academic groups are called the Armed Forces Institute of Regenerative Medicine. The consortia, working with the U.S. Army Institute of Surgical Research, is dedicated to repairing battlefield injuries using the body's natural healing powers to restore or replace damaged tissue and organs.
It’s important work for North Carolina, home to some of the nation’s most prominent military bases. And these therapies developed for the battlefield will ultimately be used everywhere.